RNA, U2 small nuclear 69, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-69P profile across patient tissues and cancer cell-line models. RNU2-69P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU2-69P is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RNU2-69P RNA expression shows 11,794 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LIHC, HNSC, and DLBC as cancer lineages where RNU2-69P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-69P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-69P survival associations across molecular data types. RNU2-69P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-69P RNA expression–survival associations across cancer types. High RNU2-69P expression shows unfavorable associations in LIHC, READ, KIRP, LAML, UVM and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU2-69P RNA expression.
This table summarizes RNU2-69P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-69P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-69P shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, BLCA, LUSC and LUAD. The HNSC box plot shows higher RNU2-69P RNA expression in tumor versus normal tissue (log2 FC = +0.464, t-test p = .009).
This table shows molecular features associated with RNU2-69P in patient tissues and cancer cell lines. In patient samples, RNU2-69P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
